|Bid||76.90 x 900|
|Ask||77.19 x 900|
|Day's Range||75.21 - 77.78|
|52 Week Range||64.08 - 127.77|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||22.18|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we'll show how Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Read More...
Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Jay Luly has been the CEO of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) since 2003. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
Warning! GuruFocus has detected 4 Warning Signs with ENTA. For the last quarter Enanta Pharmaceuticals Inc reported a revenue of $67.2 million, compared with the revenue of $75.93 million during the same period a year ago. For the last five years Enanta Pharmaceuticals Inc had an average revenue growth rate of 37% a year.
The Watertown, Massachusetts-based company said it had profit of $1.30 per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
Enanta Pharmaceuticals (NASDAQ:ENTA) has been in the news recently. Before I get around to what’s been happening with ENTA stock recently, it may help to get a broader understanding of how the company operates and what exactly it does. What used to be a fairly typical model, where you discover a drug, run it through the various drug trials, build a marketing plan and sell the drug, has now become much more focused.
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 1.04% and 1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Watertown, Massachusetts-based company said it had profit of 97 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.